AA
LXRX icon

ALPS Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

ALPS Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-35,528
Closed -$510K – 730
2016
Q2 		$510K Sell
35,528
-2,609
-7% -$35.4K ﹤0.01% 257
2016
Q1 		$456K Buy
+38,137
New +$400K ﹤0.01% 320

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ALPS Advisors's LXRX Position: Q3 2016 in Review

ALPS Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2016, closing a stake of 35,528 shares — an estimated $510K sold.

ALPS Advisors first reported a position in LXRX in Q1 2016 and held it in 2 quarters. The position peaked at $510K in Q2 2016. 144 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

  • ALPS Advisors reported no remaining Lexicon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • ALPS Advisors sold 35,528 Lexicon Pharmaceuticals shares in Q3 2016, an estimated $510K.
  • ALPS Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • ALPS Advisors's Lexicon Pharmaceuticals position peaked at $510K in Q2 2016.
  • 144 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on ALPS Advisors's 13F filing for Q3 2016, filed 2 Nov 2016.